Arterium Corporation now offers self-produced insulins

Arterium Corporation* keeps expanding its portfolio of the medicinal products used in endocrinology. In September, the company launched genetically engineered insulins under the trade names Insular Activ and Insular Stabil. Arterium Corporation thus added two new medicinal products to its product range: Insular Activ (3 ml cartridges, 5 cartridges per a carton; 5 ml vials, 5 vials per a carton) and Insular Stabil (3 ml cartridges, 5 cartridges per a carton; 5 ml vials, 5 vials per a carton).
Both are human insulins produced using recombinant DNA technologies. Insular Activ is a short-acting insulin preparation and Insular Stabil—a medium-duration action insulin. Both are used in diabetes mellitus treatment.
Insular Activ and Insular Stabil are registered in Ukraine by Kievmedpreparat.
*Arterium Corporation—Arterium Corporation itself and its two divisions—Kievmedpreparat and Galychpharm.

The information is provided for medical and pharmaceutical personnel only and shall be used exclusively in relevant professional activities. The information given here is abridged. For full information about Insular Activ and Insular Stabil, refer to the instruction for their medical use.
This website is a specialised publication intended for medical and pharmaceutical personnel only.